Skip to main content
SpringerLink
Log in

Radiopharmaceuticals for Prostate Cancer

  • Chapter
  • First Online:
Chemotherapy and Immunotherapy in Urologic Oncology

  • 526 Accesses

Abstract

A high percentage of patients with metastatic prostate cancer have evidence of bone metastases that are either symptomatic or visible on radiographic imaging (Roodman, N Engl J Med 350:1655–1664, 2004). Patients with osteoblastic metastatic disease often experience pain and have a high risk for pathologic fractures due to compromise of the affected bone. Therefore, treatment of the pain and complications from bone metastases can become complicated and costly (Roodman, N Engl J Med 350:1655–1664, 2004). Radiopharmaceuticals can be used in the treatment of bone metastases from prostate cancer. Strontium-89 and samarium-153 have been approved for the palliative treatment of bone metastases to decrease pain but have not been shown to have survival benefit. Radium-223 has been shown to be effective for pain control, as well as providing a survival benefit, for patients with castrate-resistant prostate cancer involving bone without visceral metastatic disease. This chapter discusses the characteristics of each radiopharmaceutical agent, as well as important information for managing patients undergoing treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roodman GD. Mechanisms of bone metastasis [internet]. N Engl J Med. 2004;350:1655–64; [cited 9 Dec 2018]. Available from https://www.nejm.org/doi/full/10.1056/NEJMra030831.

    Article  CAS  Google Scholar 

  2. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone [internet]. Eur J Cancer Clin Oncol. 1991;27(8):954–8; [cited 7 Feb 2019]. Available from https://www.sciencedirect.com/science/article/pii/027753799190257E. https://doi.org/10.1016/0277-5379(91)90257-E.

    Article  CAS  Google Scholar 

  3. European Medicines Agency. Xofigo [internet]. London: European Medicines Agency; 2018; [cited 7 Feb 2019]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/xofigo#all-documents-section.

    Google Scholar 

  4. Full prescribing information Xofigo (radium-223 dichloride) [internet]. Whippany: Bayer HealthCare Pharmaceuticals, Inc; c2013. Xofigo; [revised 2018 Aug; cited 10 Feb 2019]; [about 14 pages]. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf.

  5. Metastron (strontium-89 chloride injection) [internet]. Arlington Heights: GE Healthcare; c2013. Metastron [revised 2013 Dec; cited 10 Feb 2019]; [about 7 pages]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020134s012lbl.pd.f

  6. Quadramet (samarium sm-153 Lexidronam injection) [internet]. N. Billerica: Lantheus Medical Imaging, Inc; c2018. Quadramet; [revised 2018 Mar; cited 10 Feb 2019]; [about 2 pages]. Available from http://www.lantheus.com//assets/Quadramet-US-PI-513145-0318-mktg.pdf.

  7. Lexicomp [internet]. Hudson: Wolters Kluwer; c2019. Samarium Sm-153 Lexidronam [updated 4 Dec 2018; cited 10 Feb 2019]; [about 9 pages]. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/3509453?hl=480430.

  8. Lexicomp [internet]. Hudson: Wolters Kluwer; c2019. Radium-223 [updated 24 Jan 2019; cited 10 Feb 2019]; [about 9 pages]. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/4487822?hl=576710#.

  9. Lexicomp [internet]. Hudson: Wolters Kluwer; c2019. Strontium-89 [updated 5 Jan 2019; cited 10 Feb 2019]; [about 8 pages]. Available from: http://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/7705?hl=6990.

  10. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Alpha emitter Radium-223 and survival in metastatic prostate cancer [internet]. N Engl J Med. 2013;369:213–23; [cited 9 Dec 2018]. Available from https://www.nejm.org/doi/full/10.1056/NEJMoa1213755.

    Article  CAS  Google Scholar 

  11. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial [internet]. Lancet. 2001;357:336–41; [cited 7 Feb 2019]. Available from https://www.sciencedirect.com/science/article/pii/S0140673600036394?via%3Dihub. https://doi.org/10.1016/S0140-6736(00)03639-4.

    Article  CAS  PubMed  Google Scholar 

  12. Sartor O, Heinrich D, Mariados N, Mendez Vidal MJ, Keizman D, et al. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases [internet]. Ann Oncol. 2017;28(10):2464–71; [cited 9 Dec 2018]. Available from https://academic.oup.com/annonc/article/28/10/2464/3978060.

    Article  CAS  Google Scholar 

  13. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial [internet]. Lancet Oncol. 2014;15(12):1397–406; [cited 15 Dec 2018]. Available from https://www.ncbi.nlm.nih.gov/pubmed/25439694. https://doi.org/10.1016/S1470-2045(14)70474-7.

    Article  CAS  PubMed  Google Scholar 

  14. Bruland O, Nilsson S, Fisher DR, Larson RH. High-linear transfer irradiation targeted to skeletal metastases by the α-emitter 223Ra: adjuvant or alternative to conventional modalities? [internet]. Clin Cancer Res. 2006;12:6250s–7s; [cited 5 Jan 2019]. Available from http://clincancerres.aacrjournals.org/content/clincanres/12/20/6250s.full.pdf.

    Article  CAS  Google Scholar 

  15. Das T, Pillai MRA. Options to meet future global demand of radionuclides for radionuclide therapy [internet]. Nucl Med Biol. 2013;40(1):23–32; [cited 5 Jan 2019]. Available from https://www.sciencedirect.com/science/article/pii/S0969805112002521.

    Article  CAS  Google Scholar 

  16. Sartor O. Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease [internet]. Rev Urol. 2004;6(Suppl 10):S3–S12; [cited 6 Jan 2019]. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472939/.

    PubMed  PubMed Central  Google Scholar 

  17. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, et al. Palliation of pain associated with metastatic bone cancer using sarmarium-153 lexidronam: a double-blind placebo-controlled clinical trial [internet]. J Clin Oncol. 1998;16(4):1574–81; [cited 6 Jan 2019]. Available from http://ascopubs.org/doi/pdf/10.1200/JCO.1998.16.4.1574.

    Article  CAS  Google Scholar 

  18. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer [internet]. Urology. 2004;63(5):940–5; [cited 6 Jan 2019]. Available from https://www.sciencedirect.com/science/article/pii/S0090429504001438?via%3Dihub.

    Article  Google Scholar 

  19. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer [internet]. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13; [cited 30 Jan 2019]. Available from https://www.sciencedirect.com/science/article/pii/036030169390309J?via%3Dihub. https://doi.org/10.1016/0360-3016(93)90309-J.

    Article  CAS  PubMed  Google Scholar 

  20. James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, et al. Clinical outcomes and survival following treatment of metastatic castrate-refractory prostate cancer with docetaxel alone or with strontium-89, zoledronic acid, or both. The TRAPEZE randomized clinical trial [internet]. JAMA Oncol. 2016;2(4):493–9; [cited 30 Jan 2019]. Available from https://jamanetwork.com/journals/jamaoncology/fullarticle/2482917. https://doi.org/10.1001/jamaoncol.2015.5570.

    Article  PubMed  Google Scholar 

  21. van der Doelen MJ, Mehra N, Hemsen R, Janssen MJR, Gerritsen WR, van Oort IM. Patient selection for radium-223 therapy in patients with bone metastatic castration-resistant prostate cancer: new recommendations and future perspectives [internet]. Clin Genitourin Cancer. 17:79: Online 2018 November 22 [cited 7 Feb 2019]. Available from https://www.sciencedirect.com/science/article/pii/S1558767318307109#bib34. https://doi.org/10.1016/j.clgc.2018.11.008.

  22. Nevedomskaya E, Baumgart SJ, Haendler B. Recent advances in prostate cancer treatment and drug discovery [internet]. Int J Mol Sci. 2018;19(5):1359; [cited 10 Feb 2019]. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983695/. https://doi.org/10.3390/ijms19051359.

    Article  CAS  PubMed Central  Google Scholar 

  23. Ferdinandus J, Violet J, Sandhu S, Hofman MS. Prostate-specific membrane antigen theranostics: therapy with lutetium-177 [internet]. Curr Opin Urol. 2018;28(2):197–204; [cited 10 Feb 2019]. Available from https://journals.lww.com/co-urology/fulltext/2018/03000/Prostate_specific_membrane_antigen_theranostics__.17.aspx. https://doi.org/10.1097/MOU.0000000000000486.

    Article  PubMed  Google Scholar 

  24. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy [internet]. J Med Radiat Sci. 2017;64(1):52–60; [cited 10 Feb 2019]. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355374/. https://doi.org/10.1002/jmrs.227.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Ann E. Donnelly & Mark D. Hurwitz

Authors
  1. Ann E. Donnelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark D. Hurwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ann E. Donnelly .

Editor information

Editors and Affiliations

  1. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Edouard J. Trabulsi

  2. Department of Urology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Costas D. Lallas

  3. Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA

    Anne E. Lizardi-Calvaresi

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Donnelly, A.E., Hurwitz, M.D. (2021). Radiopharmaceuticals for Prostate Cancer. In: Trabulsi, E.J., Lallas, C.D., Lizardi-Calvaresi, A.E. (eds) Chemotherapy and Immunotherapy in Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-52021-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52021-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52020-5

  • Online ISBN: 978-3-030-52021-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation